Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
On 4 Aug 2025 Medicus Pharma (MDCX) filed an 8-K announcing a non-binding Memorandum of Understanding (MoU) with Boston-based Helix Nanotechnologies. The parties intend to merge HelixNano’s proprietary mRNA vaccine platform with Medicus’ microneedle array (MNA) delivery technology to create thermostable, needle-free vaccines for infectious diseases.
The MoU outlines: (i) good-faith negotiations to form a joint venture for co-development and commercialisation; and (ii) an immediate collaborative project to manufacture clinical-grade MNA-loaded doses of HelixNano’s candidate HN-0001 for a Phase 1 bridging study comparing intramuscular versus intradermal delivery. Except for limited sections, the MoU is expressly non-binding; either party may withdraw until definitive agreements are executed. No financial terms, milestones, equity allocations or timelines were disclosed, and the filing contains no revenue or earnings data. A press release (Exhibit 99.1) accompanies the report, while Item 9.01 lists standard exhibit references.